<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphar.2020.00984</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting &#x3b2;-Catenin Signaling by Natural Products for Cancer Prevention and Therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Wen-Kai</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Zhi-Yuan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Li</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/593060"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mo</surname>
<given-names>Shaowei</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Beihua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheng</surname>
<given-names>Xiang-Dong</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Qin</surname>
<given-names>Jiang-Jiang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/480586"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>College of Pharmaceutical Sciences, Zhejiang Chinese Medical University</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>The First Affiliated Hospital of Zhejiang Chinese Medical University</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Xu Zhang, Jiangsu University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Wen Zhou, Guangzhou University of Chinese Medicine, China; Xin Luan, Shanghai University of Traditional Chinese Medicine, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Jiang-Jiang Qin, <email xlink:href="mailto:jqin@zcmu.edu.cn">jqin@zcmu.edu.cn</email>; <email xlink:href="mailto:zylysjtu@hotmail.com">zylysjtu@hotmail.com</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>984</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>05</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>06</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2020 Yu, Xu, Yuan, Mo, Xu, Cheng and Qin</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Yu, Xu, Yuan, Mo, Xu, Cheng and Qin</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The mutations and deregulation of Wnt signaling pathway occur commonly in human cancer and cause the aberrant activation of &#x3b2;-catenin and &#x3b2;-catenin-dependent transcription, thus contributing to cancer development and progression. Therefore, &#x3b2;-catenin has been demonstrated as a promising target for cancer prevention and therapy. Many natural products have been characterized as inhibitors of the &#x3b2;-catenin signaling through down-regulating &#x3b2;-catenin expression, modulating its phosphorylation, promoting its ubiquitination and proteasomal degradation, inhibiting its nuclear translocation, or other molecular mechanisms. These natural product inhibitors have shown preventive and therapeutic efficacy in various cancer models <italic>in vitro</italic> and <italic>in vivo</italic>. In the present review, we comprehensively discuss the natural product &#x3b2;-catenin inhibitors, their <italic>in vitro</italic> and <italic>in vivo</italic> anticancer activities, and underlying molecular mechanisms. We also discuss the current &#x3b2;-catenin-targeting strategies and other potential strategies that may be examined for identifying new &#x3b2;-catenin inhibitors as cancer preventive and therapeutic drugs.</p>
</abstract>
<kwd-group>
<kwd>&#x3b2;-catenin</kwd>
<kwd>cancer prevention and therapy</kwd>
<kwd>degradation</kwd>
<kwd>inhibitors</kwd>
<kwd>natural products</kwd>
<kwd>phosphorylation</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="83"/>
<page-count count="12"/>
<word-count count="6331"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>&#x3b2;-Catenin was initially discovered as one of the E-cadherin-associated molecules on the cell membrane and the E-cadherin/&#x3b2;-catenin complex contributes to Ca<sup>2+</sup>-dependent cell-cell adhesion (<xref ref-type="bibr" rid="B41">Ozawa et&#xa0;al., 1989</xref>; <xref ref-type="bibr" rid="B42">Ozawa et&#xa0;al., 1990</xref>). &#x3b2;-Catenin was found to play an essential role in the embryonic development of <italic>Drosophila melanogaster</italic> (<xref ref-type="bibr" rid="B70">Wieschaus et&#xa0;al., 1984</xref>). In the saturation mutagenesis screens for identifying genes that regulate the segmentation of <italic>Drosophila</italic> embryo, the <italic>Drosophila</italic> ortholog of the mammalian &#x3b2;-catenin gene (<italic>CTNNB1</italic>), termed <italic>armadillo</italic> has been found to affect the formation of denticles and naked belts (<xref ref-type="bibr" rid="B70">Wieschaus et&#xa0;al., 1984</xref>). Further analysis has characterized the Wnt/&#x3b2;-catenin pathway by demonstrating the critical role of Wnt proteins in activating the &#x3b2;-catenin signaling pathway (<xref ref-type="bibr" rid="B51">Riggleman et&#xa0;al., 1990</xref>). In the canonical Wnt/&#x3b2;-catenin signaling pathway, &#x3b2;-catenin functions as a coactivator of the transcription factor T cell factor/lymphocyte enhancer factor (TCF/LEF) and promotes the transcription of Wnt target genes, which are responsible for controlling cell fate in various diseases, including cancer (<xref ref-type="bibr" rid="B12">Cui et&#xa0;al., 2018</xref>).</p>
<p>&#x3b2;-Catenin is overexpressed and constitutively activated in human cancer and contributes to cancer initiation, progression, metastasis, drug resistance, and immune evasion (<xref ref-type="bibr" rid="B43">Pai et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B12">Cui et&#xa0;al., 2018</xref>). Targeting &#x3b2;-catenin signaling has been proposed as a promising strategy to develop effective anticancer agents (<xref ref-type="bibr" rid="B50">Qin et&#xa0;al., 2018b</xref>; <xref ref-type="bibr" rid="B11">Cheng et&#xa0;al., 2019</xref>). Recent advances in understanding the protein structures of &#x3b2;-catenin alone and complexed with its coactivators have promoted the design and development of specific small-molecule inhibitors (<xref ref-type="bibr" rid="B26">Krishnamurthy and Kurzrock, 2018</xref>; <xref ref-type="bibr" rid="B79">Zhang X. et&#xa0;al., 2020</xref>). These &#x3b2;-catenin signaling inhibitors have shown anticancer efficacy in preclinical settings, and some of them have entered clinical trials, such as PRI-724 (<xref ref-type="bibr" rid="B26">Krishnamurthy and Kurzrock, 2018</xref>). However, none of these &#x3b2;-catenin inhibitors has been approved for clinical use yet. It is still urgently needed to identify more specific, safe, and effective &#x3b2;-catenin inhibitors for cancer treatment.</p>
<p>Natural products and their derivatives represent a major source for anticancer drug discovery (<xref ref-type="bibr" rid="B45">Qian et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B48">Qin et&#xa0;al., 2017</xref>). Over the past few decades, about 33.5% of FDA-approved anticancer drug entities are identified from natural products or their derivatives (<xref ref-type="bibr" rid="B38">Newman and Cragg, 2020</xref>). Many natural products have been found to exert their anticancer activity by inhibiting oncoproteins (e.g. &#x3b2;-catenin and MDM2) and/or reactivating tumor suppressors (e.g. p53 and Puma) (<xref ref-type="bibr" rid="B30">Li et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B49">Qin et&#xa0;al., 2018a</xref>; <xref ref-type="bibr" rid="B66">Wang W. et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B68">Wang et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B78">Zhang J. et&#xa0;al., 2020</xref>). It has also been reported that natural products can enhance the chemosensitivity of cancer cells by suppressing the functions of drug resistance-related proteins (<xref ref-type="bibr" rid="B16">Feng et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B15">Dong et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B75">Yuan et&#xa0;al., 2020</xref>). Recent studies have identified several natural products with potent inhibitory effects on the &#x3b2;-catenin signaling and shown promising anticancer efficacy <italic>in vitro</italic> and <italic>in vivo</italic>, such as baicalin (<xref ref-type="bibr" rid="B80">Zhou et&#xa0;al., 2017</xref>), arctigenin (<xref ref-type="bibr" rid="B27">Lee et&#xa0;al., 2017</xref>), and rhein (<xref ref-type="bibr" rid="B33">Liu et&#xa0;al., 2018</xref>). In the present review, we comprehensively discuss the natural products that target the &#x3b2;-catenin signaling, their <italic>in vitro</italic> and <italic>in vivo</italic> anticancer activities, and underlying molecular mechanisms. Moreover, we summarize known natural-product-based &#x3b2;-catenin-targeting strategies and propose new strategies that may be used to identify more specific and effective &#x3b2;-catenin inhibitors for cancer prevention and therapy.</p>
</sec>
<sec id="s2">
<title>Wnt/&#x3b2;-Catenin Signaling Pathway</title>
<p>The Wnt/&#x3b2;-catenin pathway (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>) plays an important role in cancer development and progression by promoting the cytoplasmic accumulation and nuclear translocation of &#x3b2;-catenin and activating the transcription of genes related to cancer cell proliferation, cell cycle progression, anti-apoptosis, migration, invasion, and drug resistance (<xref ref-type="bibr" rid="B26">Krishnamurthy and Kurzrock, 2018</xref>). In the absence of Wnt stimulation, &#x3b2;-catenin is phosphorylated by the destruction complex (<xref ref-type="fig" rid="f1">
<bold>Figure 1A</bold>
</xref>), which includes Axin, adenomatous polyposis coli (APC), glycogen synthase kinase 3 (GSK3), and casein kinase 1&#x3b1; (CK1&#x3b1;) (<xref ref-type="bibr" rid="B58">Stamos and Weis, 2013</xref>). When &#x3b2;-catenin is recruited to the destruction complex, CK1&#x3b1; initially phosphorylates &#x3b2;-catenin at Ser45 and GSK3&#x3b2; further promotes &#x3b2;-catenin phosphorylation at Ser33, Ser37, and Thr41 (<xref ref-type="bibr" rid="B2">Amit et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B31">Liu et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B71">Wu and He, 2006</xref>). Subsequently, the phosphorylated &#x3b2;-catenin is recognized and ubiquitinated by the E3 ligase protein &#x3b2;-transducin repeat-containing protein (&#x3b2;-TrCP), which consequently results in the proteasomal degradation of &#x3b2;-catenin (<xref ref-type="bibr" rid="B1">Aberle et&#xa0;al., 1997</xref>; <xref ref-type="bibr" rid="B40">Orford et&#xa0;al., 1997</xref>; <xref ref-type="bibr" rid="B58">Stamos and Weis, 2013</xref>).</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>The Wnt/&#x3b2;-catenin signaling pathway. <bold>(A)</bold> In the Wnt-off state, the &#x3b2;-catenin destruction complex is formed by Axin, APC, GSK3&#x3b2;, and CK1&#x3b1; and promotes the phosphorylation of &#x3b2;-catenin. The E3 ligase &#x3b2;-TrCP further induces &#x3b2;-catenin ubiquitination and proteasomal degradation. E-cadherin and &#x3b2;-catenin also form complex to enhance cell adhesion. <bold>(B)</bold> In the Wnt-on state, Wnt proteins bind to Frizzled receptor and LRP co-receptor and recruit and activate Dishevelled, which further inhibits the activity of GSK3&#x3b2; and releases &#x3b2;-catenin from the destruction complex. The stable &#x3b2;-catenin subsequently translocates into the nucleus, interacts with TCF/LEF, and promotes the transcription of its down-stream target genes. APC, adenomatous polyposis coli; &#x3b2;-TrCP, &#x3b2;-Transducin repeat-containing protein; CK1&#x3b1;, casein kinase 1&#x3b1;; GSK3&#x3b2;, glycogen synthase kinase 3&#x3b2;; LRP, low-density lipoprotein receptor-related protein; TCF/LEF, T cell factor/lymphocyte enhancer factor.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fphar-11-00984-g001.tif"/>
</fig>
<p>When the Wnt ligands bind to the cysteine-rich domain (CRD) of Frizzled (FZD) receptors (<xref ref-type="fig" rid="f1">
<bold>Figure 1B</bold>
</xref>), the FZD co-receptors LRP5/6 (low-density lipoprotein receptor-related protein 5/6) will be recruited to form complexes with FZD and then phosphorylated, which further causes the disassembly of the destruction complex and the stabilization and accumulation of &#x3b2;-catenin in the cytoplasm (<xref ref-type="bibr" rid="B11">Cheng et&#xa0;al., 2019</xref>; <xref ref-type="bibr" rid="B79">Zhang X. et&#xa0;al., 2020</xref>). The Wnt/FZD/LRP complex also activates Dishevelled, which further inhibits GSK3&#x3b2; and prevents &#x3b2;-catenin phosphorylation and inactivation (<xref ref-type="bibr" rid="B11">Cheng et&#xa0;al., 2019</xref>). The stable &#x3b2;-catenin then translocates into the nucleus and interacts with TCF/LEF to form the &#x3b2;-catenin/TCF/LEF complex, thereby activating the transcription of downstream target genes (<xref ref-type="bibr" rid="B26">Krishnamurthy and Kurzrock, 2018</xref>).</p>
</sec>
<sec id="s3">
<title>Natural Product Inhibitors of &#x3b2;-Catenin Signaling Pathway</title>
<p>As a well-recognized cancer driver gene, &#x3b2;-catenin has been demonstrated as a molecular target for developing anticancer drugs. Small-molecule inhibitors have been designed and synthesized for inhibiting the &#x3b2;-catenin/TCF binding or promoting &#x3b2;-catenin phosphorylation and ubiquitination (<xref ref-type="bibr" rid="B79">Zhang X. et&#xa0;al., 2020</xref>). Natural product-based libraries have also been frequently screened, leading to the identification of several &#x3b2;-catenin inhibitors (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). These natural products have been found to inhibit the &#x3b2;-catenin signaling through different molecular mechanisms (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>), including, but not limited to, 1) down-regulating &#x3b2;-catenin expression, 2) modulating &#x3b2;-catenin phosphorylation, 3) promoting &#x3b2;-catenin protein degradation, 4) inhibiting &#x3b2;-catenin nuclear translocation, and others.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Natural product &#x3b2;-catenin inhibitors and their activities and mechanisms of action.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Inhibitors</th>
<th valign="top" align="center">Mechanisms of action</th>
<th valign="top" align="center">
<italic>In vitro</italic> activity</th>
<th valign="top" align="center">
<italic>In vivo</italic> activity</th>
<th valign="top" align="center">References</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" colspan="5" align="left">
<bold>
<italic>Strategy 1. Down-regulate &#x3b2;-catenin expression</italic>
</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Baohuoside-I</td>
<td valign="top" align="left">Down-regulates the expression of &#x3b2;-catenin and its downstream targets at both mRNA and protein levels</td>
<td valign="top" align="left">Inhibits cell growth and induces apoptosis in esophageal cancer Eca109 cells</td>
<td valign="top" align="left">Suppresses tumor growth in mice bearing Eca109 xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B63">Wang et&#xa0;al., 2011</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Baicalin</td>
<td valign="top" align="left">Down-regulates &#x3b2;-catenin expression</td>
<td valign="top" align="left">Inhibits migration and invasion in breast cancer MDA-MB-231 and 4T1 cells</td>
<td valign="top" align="left">Prevents metastasis to liver and lung in mice bearing 4T1 xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B80">Zhou et&#xa0;al., 2017</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Arctigenin</td>
<td valign="top" align="left">Down-regulates &#x3b2;-catenin expression in an ER-dependent manner</td>
<td valign="top" align="left">Inhibits proliferation and induces apoptosis in ER positive breast cancer MCF7 cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B27">Lee et&#xa0;al., 2017</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Lignan E2S</td>
<td valign="top" align="left">Down-regulates &#x3b2;-catenin expression</td>
<td valign="top" align="left">Inhibits the viability and induces cell cycle arrest at the G1 phase in colon cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B72">Xia et&#xa0;al., 2013</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">&#x3b2;-Elemene</td>
<td valign="top" align="left">Down-regulates the expression of &#x3b2;-catenin and TCF7</td>
<td valign="top" align="left">Inhibits cell viability, induces cell cycle arrest at G1 phase and apoptosis, and prevents migration and invasion in cervical cancer SiHa cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B65">Wang L. t&#xa0;al., 2018</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Shizukaol D</td>
<td valign="top" align="left">Down-regulates the expression of &#x3b2;-catenin, LRP, Dvl2, and Axin2</td>
<td valign="top" align="left">Inhibits cell growth and induces apoptosis in liver cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B61">Tang et&#xa0;al., 2016</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">20(<italic>S</italic>)-25-OCH<sub>3</sub>-PPD</td>
<td valign="top" align="left">Down-regulates the expression of &#x3b2;-catenin and its downstream targets</td>
<td valign="top" align="left">Inhibits proliferation and induces apoptosis in colon and lung cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B5">Bi et&#xa0;al., 2009</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">20(<italic>S</italic>)-ginsenoside Rh2</td>
<td valign="top" align="left">Down-regulates &#x3b2;-catenin expression at both mRNA and protein levels</td>
<td valign="top" align="left">Inhibits proliferation and induces cell cycle arrest at G0/G1 phase and apoptosis in leukemia KG&#x2212;1a cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B6">Chen et&#xa0;al., 2016</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">&#x3b2;-Sitosterol</td>
<td valign="top" align="left">Down-regulates &#x3b2;-catenin expression</td>
<td valign="top" align="left">Inhibit growth and induces apoptosis in colon cancer COLO 320 DM cells</td>
<td valign="top" align="left">Reduces the number of aberrant crypt and crypt multiplicity in DMH-treated rats</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B4">Baskar et&#xa0;al., 2010</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Periplocin</td>
<td valign="top" align="left">Down-regulates &#x3b2;-catenin expression</td>
<td valign="top" align="left">Inhibits the proliferation of colon cancer HCT116 cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B25">Kim et&#xa0;al., 2017</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Evodiamine</td>
<td valign="top" align="left">Down-regulates &#x3b2;-catenin expression</td>
<td valign="top" align="left">Inhibits proliferation, invasion, and migration of HCC HepG2 and SMMC-7721 cells</td>
<td valign="top" align="left">Suppresses tumor growth and angiogenesis in mice bearing H22 and SMMC-7721 xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B52">Shi et&#xa0;al., 2016</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Resveratrol</td>
<td valign="top" align="left">Down-regulates the expression of &#x3b2;-catenin and c-Myc</td>
<td valign="top" align="left">Inhibits cell proliferation and induces apoptosis in LNCaP and MES-SA cells</td>
<td valign="top" align="left">Suppresses tumor growth in mice bearing LNCaP xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B35">Mitani et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B34">Mineda et&#xa0;al., 2019</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">PEITC</td>
<td valign="top" align="left">Reduces the levels of phosphorylated GSK3&#x3b2; and &#x3b2;-catenin</td>
<td valign="top" align="left">Suppresses the properties of CSCs, inhibits proliferation, and induces apoptosis in colon cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B8">Chen et&#xa0;al., 2018</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Gigantol</td>
<td valign="top" align="left">Reduces the levels of phosphorylated LRP6,<break/>total LRP6, and cytosolic &#x3b2;-catenin</td>
<td valign="top" align="left">Inhibits the viability and migration of breast cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B74">Yu et&#xa0;al., 2018</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Polysaccharide from <italic>Phellinus linteus</italic>
</td>
<td valign="top" align="left">Down-regulates the expression of &#x3b2;-catenin and cyclin D1</td>
<td valign="top" align="left">Inhibits growth, invasion, and motility of colon cancer SW480 cells</td>
<td valign="top" align="left">Suppresses tumor growth in mice bearing SW480 xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B57">Song et&#xa0;al., 2011</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Riccardin D</td>
<td valign="top" align="left">Down-regulates the expression of &#x3b2;-catenin and cyclin D1</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">Prevents intestinal adenoma formation in <italic>APC<sup>Min/+</sup>
</italic> mice</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B32">Liu et&#xa0;al., 2012</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="5" align="left">
<bold>
<italic>Strategy 2. Modulate &#x3b2;-catenin phosphorylation</italic>
</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Fisetin</td>
<td valign="top" align="left">Induces &#x3b2;-catenin phosphorylation and inhibits the expression and nuclear translocation of TCF1 and TCF4</td>
<td valign="top" align="left">Inhibits viability and induces apoptosis in colon cancer HCT116 and HT29 cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B59">Suh et&#xa0;al., 2009</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Honokiol</td>
<td valign="top" align="left">Induces &#x3b2;-catenin phosphorylation at Ser<sup>45</sup>, Ser<sup>33/37</sup> and Thr<sup>41</sup>
</td>
<td valign="top" align="left">Inhibits the migration of NSCLC cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B55">Singh and Katiyar, 2013b</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">4&#x3b2;-HWE</td>
<td valign="top" align="left">Induces &#x3b2;-catenin phosphorylation at Ser<sup>33</sup>, Ser<sup>37</sup>, and Thr<sup>41</sup> and inhibits its nuclear translocation</td>
<td valign="top" align="left">Inhibits proliferation and induces cell cycle arrest at G0/G1 phase and apoptosis in colon cancer cells</td>
<td valign="top" align="left">Suppresses tumor growth in mice bearing HCT116 xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B73">Ye et&#xa0;al., 2019</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Ethanol extract of <italic>Scutellaria barbata</italic> D. Don</td>
<td valign="top" align="left">Induces &#x3b2;-catenin phosphorylation and reduces &#x3b2;-catenin expression</td>
<td valign="top" align="left">Inhibits the proliferation and survival of HT-29 cells</td>
<td valign="top" align="left">Suppresses tumor growth in mice bearing HT-29 xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B69">Wei et&#xa0;al., 2017</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Shikonin</td>
<td valign="top" align="left">Inhibits &#x3b2;-catenin phosphorylation at Y333</td>
<td valign="top" align="left">Inhibits proliferation, migration, and invasion of glioblastoma U87 and U251 cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B77">Zhang et&#xa0;al., 2015</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="5" align="left">
<bold>
<italic>Strategy 3. Promote &#x3b2;-catenin protein degradation</italic>
</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Wogonin</td>
<td valign="top" align="left">Promotes &#x3b2;-catenin phosphorylation and degradation</td>
<td valign="top" align="left">Inhibits proliferation and induces cell cycle arrest at G1 phase in colon cancer cells</td>
<td valign="top" align="left">Suppresses tumor growth in mice bearing HCT116 xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B20">He et&#xa0;al., 2013</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Rhein</td>
<td valign="top" align="left">Promotes &#x3b2;-catenin protein degradation in GSK3-dependent manner</td>
<td valign="top" align="left">Inhibits proliferation and induces cell cycle arrest at S phase in HepG2 and Hela cells</td>
<td valign="top" align="left">Suppresses tumor growth in mice bearing HepG2 xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B33">Liu et&#xa0;al., 2018</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Decursin</td>
<td valign="top" align="left">Promotes &#x3b2;-catenin protein degradation</td>
<td valign="top" align="left">Inhibits the proliferation of prostate cancer PC3 cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B56">Song et&#xa0;al., 2007</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">EGCG</td>
<td valign="top" align="left">Promotes &#x3b2;-catenin phosphorylation and degradation in a &#x3b2;-TrCP-dependent manner</td>
<td valign="top" align="left">Suppresses the properties of CSCs, inhibits proliferation, and induces apoptosis in colon cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B13">Dashwood et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B54">Singh and Katiyar, 2013a</xref>; <xref ref-type="bibr" rid="B39">Oh et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B7">Chen et&#xa0;al., 2017</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="5" align="left">
<bold>
<italic>Strategy 4. Inhibit &#x3b2;-catenin nuclear translocation</italic>
</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Apigenin</td>
<td valign="top" align="left">Inhibits &#x3b2;-catenin nuclear translocation</td>
<td valign="top" align="left">Inhibits proliferation and induces apoptosis in prostate cancer DU145 cells</td>
<td valign="top" align="left">Prevents prostate tumorigenesis and metastasis and improves overall survival in TRAMP mice</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B53">Shukla et&#xa0;al., 2007</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Curcumin</td>
<td valign="top" align="left">Inhibits &#x3b2;-catenin nuclear translocation and the &#x3b2;-catenin/TCF-LEF binding to the promoter DNA</td>
<td valign="top" align="left">Inhibits the viability, migration, and invasion and induces cell cycle arrest at G2/M phase and apoptosis in osteosarcoma and colon cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B23">Jaiswal et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B28">Leow et&#xa0;al., 2010</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Ellagic acid</td>
<td valign="top" align="left">Inhibits &#x3b2;-catenin nuclear translocation</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">Suppresses development of carcinomas in the DMBA-induced HBP carcinogenesis model.</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B3">Anitha et&#xa0;al., 2013</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Isoeleutherine</td>
<td valign="top" align="left">Inhibits &#x3b2;-catenin nuclear translocation and TCF/&#x3b2;-catenin transcription</td>
<td valign="top" align="left">Inhibits the viability of colon cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B29">Li et&#xa0;al., 2009</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Toxoflavin (PKF118-310)</td>
<td valign="top" align="left">Inhibits &#x3b2;-catenin nuclear translocation</td>
<td valign="top" align="left">Inhibits the viability, migration, and invasion and induces cell cycle arrest at G2/M phase and apoptosis in osteosarcoma cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B28">Leow et&#xa0;al., 2010</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="5" align="left">
<bold>
<italic>Strategy 5. Others</italic>
</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Parthenolide</td>
<td valign="top" align="left">Binds to RPL10, decreases TCF4/LEF1 protein levels by blocking protein synthesis, and inhibits Wnt/&#x3b2;-catenin signaling pathway</td>
<td valign="top" align="left">Inhibits proliferation of colon cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B83">Zhu et&#xa0;al., 2018</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Berbamine</td>
<td valign="top" align="left">Decrease &#x3b2;-catenin protein levels by binding to CaMKII &#x3b3; and inhibiting its kinase activity</td>
<td valign="top" align="left">Induces apoptotic and autophagic death of CML cells</td>
<td valign="top" align="left">Suppresses tumor growth in mice bearing TKI-resistant K562 or primary CML xenograft tumors</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B18">Gu et&#xa0;al., 2012</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">
<italic>Teucrium polium</italic> plant extract</td>
<td valign="top" align="left">Enhances the formation of E-cadherin/&#x3b2;-catenin complex and inhibits &#x3b2;-catenin phosphorylation</td>
<td valign="top" align="left">Inhibits proliferation, induces cell cycle arrest at S phase, and reduces invasion and motility of prostate cancer PC3 and DU145 cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B24">Kandouz et&#xa0;al., 2010</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Alkaloid-enriched extract of <italic>Uncaria tomentosa</italic>
</td>
<td valign="top" align="left">Inhibits Wnt/&#x3b2;-catenin signaling pathway without affecting &#x3b2;-catenin level</td>
<td valign="top" align="left">Inhibits viability of colon cancer cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B19">Gurrola-Diaz et&#xa0;al., 2011</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Dinactin</td>
<td valign="top" align="left">Inhibits Wnt/&#x3b2;-catenin signaling pathway</td>
<td valign="top" align="left">Inhibits the proliferation and induces cell cycle arrest at G1/S phase in HCT116 and HepG2 cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B22">Hussain et&#xa0;al., 2019</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Caffeoylquinic acids</td>
<td valign="top" align="left">Inhibits TCF-4 expression</td>
<td valign="top" align="left">Inhibits the viability of colon cancer HCT116 cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B60">Taira et&#xa0;al., 2014</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">Chromomycins A2 and A3</td>
<td valign="top" align="left">Inhibits TCF/&#x3b2;-catenin transcription</td>
<td valign="top" align="left">Inhibits the viability of gastric adenocarcinoma cells</td>
<td valign="top" align="left">NR</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B62">Toume et&#xa0;al., 2014</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>4&#x3b2;-HWE, 4&#x3b2;-hydroxy-withanolide E; CML, chronic myeloid leukemia; CSCs, cancer stem cells; DMBA, 7,12-dimethylbenz[a]anthracene; DMH, 1,2-dimethylhydrazine; EGCG, epigallocatechin-3-gallate; EMT, epithelial-to-mesenchymal transition; ER, estrogen receptor; HBP, hamster buccal pouch; HCC, hepatocellular carcinoma; NR, not reported; NSCLC, non-small cell lung cancer; PEITC, phenethyl isothiocyanate; TKI, tyrosine kinase inhibitor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f2" position="float">
<label>Figure 2</label>
<caption>
<p>Natural products targeting the &#x3b2;-catenin signaling pathway for cancer therapy. Many natural products have been discovered to inhibit the &#x3b2;-catenin signaling pathway through (1) down-regulating &#x3b2;-catenin expression, (2) modulating &#x3b2;-catenin phosphorylation, (3) promoting &#x3b2;-catenin protein degradation, (4) inhibiting &#x3b2;-catenin nuclear translocation, and other mechanisms of action. 20(<italic>S</italic>)-Rh2, 20(<italic>S</italic>)-ginsenoside Rh2; 4&#x3b2;-HWE, 4&#x3b2;-Hydroxywithanolide E; AEUT, alkaloid-enriched extract of <italic>Uncaria tomentosa</italic>; APC, adenomatous polyposis coli; &#x3b2;-TrCP, &#x3b2;-Transducin repeat-containing protein; CK1&#x3b1;, casein kinase 1&#x3b1;; EGCG, epigallocatechin-3-gallate; EESB, ethanol extract of <italic>Scutellaria barbata</italic> D. Don; GS25, 20(<italic>S</italic>)-25-OCH<sub>3</sub>-PPD; GSK3&#x3b2;, glycogen synthase kinase 3&#x3b2;; LRP, low-density lipoprotein receptor-related protein; PEITC, phenethyl isothiocyanate; PPL, polysaccharides from <italic>Phellinus linteus</italic>; TCF/LEF, T cell factor/lymphocyte enhancer factor; TPPE, <italic>Teucrium polium</italic> plant extract.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fphar-11-00984-g002.tif"/>
</fig>
<sec id="s3_1">
<title>Down-Regulate &#x3b2;-Catenin Expression</title>
<p>The majority of natural product inhibitors have been reported to down-regulate the expression of &#x3b2;-catenin and/or its coactivators, thereby inhibiting the transcription of its downstream target genes (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). Flavonoids are a class of ubiquitous polyphenolic natural products in medicinal plants and have recently been found to exert anticancer activities by targeting the &#x3b2;-catenin signaling (<xref ref-type="bibr" rid="B10">Cheng et&#xa0;al., 2011b</xref>; <xref ref-type="bibr" rid="B63">Wang et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B81">Zhu et&#xa0;al., 2012a</xref>; <xref ref-type="bibr" rid="B80">Zhou et&#xa0;al., 2017</xref>). Baohuoside-I, a flavonoid from <italic>Cortex periplocae</italic> has been reported to down-regulate the expression of &#x3b2;-catenin and its downstream target gene Survivin and Cyclin D1 at both protein and mRNA levels (<xref ref-type="bibr" rid="B63">Wang et&#xa0;al., 2011</xref>). Wang et al. have also demonstrated that baohuoside-I inhibits the viability and induces apoptosis in esophageal cancer Eca109 cells <italic>in vitro</italic> and suppresses the growth of Eca109 xenograft tumors <italic>in vivo</italic> (<xref ref-type="bibr" rid="B63">Wang et&#xa0;al., 2011</xref>). Another flavonoid baicalin has been found to inhibit the migration and invasion of triple negative breast cancer MDA-MB-231 and 4T1 cells <italic>in vitro</italic> by modulating the expression of epithelial-to-mesenchymal transition (EMT)-related proteins, including &#x3b2;-catenin (<xref ref-type="bibr" rid="B80">Zhou et&#xa0;al., 2017</xref>). Further studies have shown that baicalin prevents tumor metastasis to liver and lungs in mice bearing 4T1 xenograft tumors (<xref ref-type="bibr" rid="B80">Zhou et&#xa0;al., 2017</xref>). Importantly, the expression level of &#x3b2;-catenin is critical for the anti-metastatic activity of baicalin (<xref ref-type="bibr" rid="B80">Zhou et&#xa0;al., 2017</xref>). However, the detailed molecular mechanisms for their inhibitory effects on &#x3b2;-catenin expression are yet to be determined.</p>
<p>Lignans as a group of diphenolic natural products have exhibited inhibitory effects on &#x3b2;-catenin expression (<xref ref-type="bibr" rid="B9">Cheng et&#xa0;al., 2011a</xref>; <xref ref-type="bibr" rid="B82">Zhu et&#xa0;al., 2012b</xref>; <xref ref-type="bibr" rid="B72">Xia et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B27">Lee et&#xa0;al., 2017</xref>). Lee et al. have recently demonstrated that &#x3b2;-catenin is a molecular target of the lignan arctigenin (<xref ref-type="bibr" rid="B27">Lee et&#xa0;al., 2017</xref>). It has been found that arctigenin inhibits the proliferation of breast cancer MCF7 cells and induces apoptosis <italic>in vitro</italic> in an estrogen receptor (ER)-dependent manner (<xref ref-type="bibr" rid="B27">Lee et&#xa0;al., 2017</xref>). Arctigenin has also been shown to decrease the expression levels of &#x3b2;-catenin and its target Cyclin D1 <italic>via</italic> an ER-dependent mechanism (<xref ref-type="bibr" rid="B27">Lee et&#xa0;al., 2017</xref>). The lignan E2S from <italic>Carya cathayensis</italic> fruits has also shown inhibitory effects on &#x3b2;-catenin expression (<xref ref-type="bibr" rid="B72">Xia et&#xa0;al., 2013</xref>). Xia et al. have reported that the lignan E2S inhibits cell viability and induces cell cycle arrest at the G1 phase in colon cancer HT29, HCT116, LoVo, and SW480 cells in a concentration-dependent manner (<xref ref-type="bibr" rid="B72">Xia et&#xa0;al., 2013</xref>). However, their <italic>in vivo</italic> efficacy and mechanisms of action should be further investigated.</p>
<p>Sesquiterpenes, especially sesquiterpene lactones are a class of natural products with diverse structures and biological activities (<xref ref-type="bibr" rid="B76">Zhang et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B64">Wang et&#xa0;al., 2014</xref>). Wang <italic>et al.</italic> have recently reported that the sesquiterpene &#x3b2;-elemene from <italic>Rhizoma zedoariae</italic> oil inhibits cell viability and induces cell cycle arrest at the G1 phase and apoptosis in cervical cancer SiHa cells (<xref ref-type="bibr" rid="B65">Wang L. t&#xa0;al., 2018</xref>). &#x3b2;-Elemene has also been shown to suppress the migration and invasion of SiHa cells (<xref ref-type="bibr" rid="B65">Wang L. t&#xa0;al., 2018</xref>). The mechanisms of action studies have found that &#x3b2;-elemene inhibits the &#x3b2;-catenin signaling by decreasing the expression levels of &#x3b2;-catenin and its coactivator TCF7 (<xref ref-type="bibr" rid="B65">Wang L. t&#xa0;al., 2018</xref>). The dimeric sesquiterpenes have shown more potent anticancer activities than their monomers by targeting oncogenic drivers (<xref ref-type="bibr" rid="B46">Qin et&#xa0;al., 2015a</xref>; <xref ref-type="bibr" rid="B47">Qin et&#xa0;al., 2015b</xref>). Tang et al. have recently identified shizukaol D, a dimeric sesquiterpene as a &#x3b2;-catenin signaling inhibitor (<xref ref-type="bibr" rid="B61">Tang et&#xa0;al., 2016</xref>). It has been found that shizukaol D inhibits cell viability and colony formation and induces apoptosis in liver cancer cells by down-regulating the expression of &#x3b2;-catenin and its upstream regulators LRP, Dvl2, and Axin2 (<xref ref-type="bibr" rid="B61">Tang et&#xa0;al., 2016</xref>). The activation of &#x3b2;-catenin by wnt3a blocks shizukaol D-induced cell growth inhibition, indicating that the &#x3b2;-catenin signaling plays a critical role in the anticancer activity of this compound (<xref ref-type="bibr" rid="B61">Tang et&#xa0;al., 2016</xref>). However, the <italic>in vivo</italic> efficacy and safety of &#x3b2;-elemene and shizukaol D have not been evaluated yet. It should also be examined whether these sesquiterpenes induce &#x3b2;-catenin degradation by disrupting the destruction complex.</p>
<p>Ginsenosides, the active components of the well-known herbal medicine <italic>Panax ginseng</italic> have shown a wide range of pharmacological activities, including anticancer activity (<xref ref-type="bibr" rid="B36">Nag et&#xa0;al., 2012</xref>). Recent studies have indicated that &#x3b2;-catenin signaling also plays an important role in the anticancer activities of ginsenosides (<xref ref-type="bibr" rid="B5">Bi et&#xa0;al., 2009</xref>; <xref ref-type="bibr" rid="B6">Chen et&#xa0;al., 2016</xref>). Bi et al. have found that ginsenoside 20(<italic>S</italic>)-25-OCH<sub>3</sub>-PPD inhibits the viability and induces apoptosis in colon and lung cancer cells by downregulating the protein expression of &#x3b2;-catenin and its targets CDK4, cyclin D1, c-Myc, and TCF4 (<xref ref-type="bibr" rid="B5">Bi et&#xa0;al., 2009</xref>). More recently, Chen et al. have reported that 20(<italic>S</italic>)-ginsenoside Rh2 inhibits cell viability and induces cell cycle arrest at the G0/G1 phase and apoptosis in leukemia KG&#x2212;1a cells by down-regulating the expression of &#x3b2;-catenin at both protein and mRNA levels (<xref ref-type="bibr" rid="B6">Chen et&#xa0;al., 2016</xref>). Nevertheless, further studies should be performed to explore the precise mechanisms of action for the ginsenoside-mediated inhibition of &#x3b2;-catenin expression.</p>
<p>Sterols from medicinal plants have recently been shown to inhibit the &#x3b2;-catenin signaling (<xref ref-type="bibr" rid="B4">Baskar et&#xa0;al., 2010</xref>; <xref ref-type="bibr" rid="B25">Kim et&#xa0;al., 2017</xref>). Baskar et al. have found that &#x3b2;-sitosterol, a sterol compound from the traditional medicinal plant <italic>Asclepias curassavica</italic> Linn. inhibits cell growth and induces apoptosis in colon cancer COLO 320 DM cells (<xref ref-type="bibr" rid="B4">Baskar et&#xa0;al., 2010</xref>). &#x3b2;-Sitosterol has also shown chemopreventive effects on 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis in rats (<xref ref-type="bibr" rid="B4">Baskar et&#xa0;al., 2010</xref>). The <italic>in vitro</italic> and <italic>in vivo</italic> anti-colon cancer activity of &#x3b2;-sitosterol has been partially attributed to the down-regulation of &#x3b2;-catenin expression by the compound (<xref ref-type="bibr" rid="B4">Baskar et&#xa0;al., 2010</xref>). Kim <italic>et al.</italic> have identified periplocin from the methanol extract of <italic>Telectadium dongnaiense</italic> bark as a new inhibitor of the &#x3b2;-catenin signaling (<xref ref-type="bibr" rid="B25">Kim et&#xa0;al., 2017</xref>). It has been reported that periplocin decreases the protein expression levels of &#x3b2;-catenin and its downstream targets, leading to the growth inhibition of colon cancer HCT116, SW480, HCT15, and LS174T cells (<xref ref-type="bibr" rid="B25">Kim et&#xa0;al., 2017</xref>). Nature-derived alkaloids have also exhibited potent anticancer activity by targeting the &#x3b2;-catenin signaling (<xref ref-type="bibr" rid="B17">Fu et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B52">Shi et&#xa0;al., 2016</xref>). Evodiamine, a quinolone alkaloid from <italic>Euodia rutaecarpa</italic> (Juss.) Benth. (Rutaceae) has been reported to inhibit the proliferation, invasion, and migration of hepatocellular carcinoma (HCC) HepG2 and SMMC-7721 cells <italic>in vitro</italic> and suppress tumor growth and angiogenesis in mice bearing H22 and SMMC-7721 xenograft tumors <italic>in vivo</italic> (<xref ref-type="bibr" rid="B52">Shi et&#xa0;al., 2016</xref>). The down-regulation of &#x3b2;-catenin protein expression by evodiamine has been found to contribute to its anti-HCC activity (<xref ref-type="bibr" rid="B52">Shi et&#xa0;al., 2016</xref>).</p>
<p>Several other natural products have been found to down-regulate the expression of &#x3b2;-catenin, including resveratrol (<xref ref-type="bibr" rid="B35">Mitani et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B34">Mineda et&#xa0;al., 2019</xref>), phenethyl isothiocyanate (PEITC) (<xref ref-type="bibr" rid="B8">Chen et&#xa0;al., 2018</xref>), gigantol (<xref ref-type="bibr" rid="B74">Yu et&#xa0;al., 2018</xref>), polysaccharide from <italic>Phellinus linteus</italic> (<xref ref-type="bibr" rid="B57">Song et&#xa0;al., 2011</xref>), and riccardin D (<xref ref-type="bibr" rid="B32">Liu et&#xa0;al., 2012</xref>). Among them, resveratrol and PEITC are two well-documented dietary anticancer chemopreventive compounds with multiple molecular targets (<xref ref-type="bibr" rid="B35">Mitani et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B8">Chen et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B34">Mineda et&#xa0;al., 2019</xref>). Recent studies have shown that resveratrol and PEITC also inhibit the &#x3b2;-catenin signaling; however, the importance of &#x3b2;-catenin in their anticancer activity is yet to be determined (<xref ref-type="bibr" rid="B35">Mitani et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B8">Chen et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B34">Mineda et&#xa0;al., 2019</xref>). Besides, gigantol from medicinal orchids and polysaccharides from <italic>Phellinus linteus</italic> have shown inhibitory effects on cancer cell growth and invasion by decreasing the protein levels of &#x3b2;-catenin and its targets (<xref ref-type="bibr" rid="B57">Song et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B74">Yu et&#xa0;al., 2018</xref>). Moreover, riccardin D from the liverwort plant <italic>Dumortiera hirsute</italic> has shown preventive effects on intestinal adenoma formation in <italic>APC</italic>
<sup>Min/+</sup> mice (<xref ref-type="bibr" rid="B32">Liu et&#xa0;al., 2012</xref>). Although riccardin D has been shown to decrease the protein expression level of &#x3b2;-catenin <italic>in vivo</italic>, it is unknown how important &#x3b2;-catenin is in its anticancer activity (<xref ref-type="bibr" rid="B32">Liu et&#xa0;al., 2012</xref>).</p>
</sec>
<sec id="s3_2">
<title>Modulate &#x3b2;-Catenin Phosphorylation</title>
<p>Considering that &#x3b2;-catenin phosphorylation by GSK3&#x3b2; and CK1&#x3b1; leads to its inactivation and degradation, directly promoting &#x3b2;-catenin phosphorylation has been proposed as an effective strategy to inhibit the &#x3b2;-catenin signaling pathway. Several natural products have recently been shown to inhibit cancer cell growth and metastasis by inducing &#x3b2;-catenin phosphorylation and inactivation (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). Suh <italic>et al.</italic> have reported that fisetin, a flavonoid commonly found in various vegetables and fruits promotes the phosphorylation of &#x3b2;-catenin and decreases its nuclear level in colon cancer cells (<xref ref-type="bibr" rid="B59">Suh et&#xa0;al., 2009</xref>). It has also been found that fisetin down-regulates the expression of TCF1 and TCF4 in the nucleus and whole cancer cells (<xref ref-type="bibr" rid="B59">Suh et&#xa0;al., 2009</xref>). Consequently, fisetin inhibits cell viability and induces apoptosis in colon cancer HCT116 and HT29 cells (<xref ref-type="bibr" rid="B59">Suh et&#xa0;al., 2009</xref>). Honokiol, a lignan from the bark of <italic>Magnolia</italic> plants has been found to induce the phosphorylation of &#x3b2;-catenin at Ser45, Ser33/37, and Thr41 and reduce the &#x3b2;-catenin protein level in the nucleus (<xref ref-type="bibr" rid="B55">Singh and Katiyar, 2013b</xref>). Singh and Katiyar have also demonstrated that honokiol suppresses the migration of non-small cell lung cancer (NSCLC) cells (<xref ref-type="bibr" rid="B55">Singh and Katiyar, 2013b</xref>). However, the effects of fisetin and honokiol on the protein stability of &#x3b2;-catenin are yet to be determined. Moreover, the <italic>in vivo</italic> efficacy of both compounds should be examined in future studies.</p>
<p>Ye <italic>et al.</italic> have recently reported that 4&#x3b2;-hydroxywithanolide E (4&#x3b2;-HWE), a natural withanolide from <italic>Physalis peruviana</italic> increases the level of phosphorylated &#x3b2;-catenin and decreases the levels of active nonphosphorylated form and total &#x3b2;-catenin in colon cancer HCT116 cells (<xref ref-type="bibr" rid="B73">Ye et&#xa0;al., 2019</xref>). 4&#x3b2;-HWE has been shown to inhibit cell viability and induce cell cycle arrest at the G0/G1 phase and apoptosis in colon cancer cells with minimal cytotoxicity against normal colonic epithelial cells (CCD-841-CoN) (<xref ref-type="bibr" rid="B73">Ye et&#xa0;al., 2019</xref>). More importantly, this compound has shown potent inhibitory effects on tumor growth in mice bearing HCT116 xenograft tumors, without causing significant changes in the average body weights of mice (<xref ref-type="bibr" rid="B73">Ye et&#xa0;al., 2019</xref>). Wei <italic>et al.</italic> have found that ethanol extract of <italic>Scutellaria barbata</italic> D. Don (EESB) inhibits the viability and proliferation of colon cancer HT-29 cells <italic>in vitro</italic> and suppresses the growth of HT-29 xenograft tumors <italic>in vivo</italic> (<xref ref-type="bibr" rid="B69">Wei et&#xa0;al., 2017</xref>). Mechanism of action studies have indicated that EESB induces &#x3b2;-catenin phosphorylation and reduces the expression level of total &#x3b2;-catenin in HT-29 cells (<xref ref-type="bibr" rid="B69">Wei et&#xa0;al., 2017</xref>). However, the active components in EESB that are responsible for EESB-induced &#x3b2;-catenin phosphorylation are yet to be determined.</p>
<p>Different from the aforementioned natural products that induce &#x3b2;-catenin phosphorylation, shikonin, an anthraquinone derivative from the root of <italic>lithospermum</italic> inhibits the phosphorylation of &#x3b2;-catenin in glioblastoma cells in a context-dependent manner. More specifically, this compound inhibits &#x3b2;-catenin phosphorylation at Tyr333 in U87 cells without altering its level in U251 cells (<xref ref-type="bibr" rid="B77">Zhang et&#xa0;al., 2015</xref>). However, shikonin has exhibited inhibitory effects on the proliferation, migration, and invasion of both U87 and U251 cell lines (<xref ref-type="bibr" rid="B77">Zhang et&#xa0;al., 2015</xref>). Further studies have indicated that shikonin also inhibits the PI3K/Akt pathway, which may also play a pivotal role in its anticancer activity (<xref ref-type="bibr" rid="B77">Zhang et&#xa0;al., 2015</xref>).</p>
</sec>
<sec id="s3_3">
<title>Promote &#x3b2;-Catenin Protein Degradation</title>
<p>Natural products that promote &#x3b2;-catenin protein degradation have been identified and shown anticancer efficacy <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>) (<xref ref-type="bibr" rid="B13">Dashwood et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B56">Song et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B20">He et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B33">Liu et&#xa0;al., 2018</xref>). He et al. have characterized wogonin, a flavonoid from a Chinese medicinal herb <italic>Scutellaria radix</italic> (also called Huang-Qin) as an inducer of &#x3b2;-catenin protein degradation (<xref ref-type="bibr" rid="B20">He et&#xa0;al., 2013</xref>). It has been found that wogonin inhibits cell viability and colony formation and induces cell cycle arrest at the G1 phase in colon cancer cells <italic>in vitro</italic>. Wogonin has also been shown to suppress the growth of HCT116 xenograft tumors <italic>in vivo</italic> (<xref ref-type="bibr" rid="B20">He et&#xa0;al., 2013</xref>). Mechanistically, wogonin promotes &#x3b2;-catenin phosphorylation and degradation by activating the destruction complex proteins GSK3&#x3b2; and Axin. It has further been found that wogonin inhibits CDK8 activity, which is at least partially responsible for the inhibition of &#x3b2;-catenin signaling by the compound (<xref ref-type="bibr" rid="B20">He et&#xa0;al., 2013</xref>). Rhein, an anthraquinone derivative of rhubarb has also been shown to promote &#x3b2;-catenin phosphorylation at Ser33 and protein degradation, in which GSK3&#x3b2; plays a critical role (<xref ref-type="bibr" rid="B33">Liu et&#xa0;al., 2018</xref>). Liu <italic>et al.</italic> have further found that rhein inhibits cell proliferation and induces cell cycle arrest at the S phase in HepG2 and Hela cells <italic>in vitro</italic> and suppresses the growth of HepG2 xenograft tumors <italic>in vivo</italic> (<xref ref-type="bibr" rid="B33">Liu et&#xa0;al., 2018</xref>).</p>
<p>Decursin, a pyranocoumarin identified from the roots of <italic>Angelica gigas</italic> Nakai has exhibited promising anti-prostate cancer efficacy (<xref ref-type="bibr" rid="B56">Song et&#xa0;al., 2007</xref>). Song <italic>et al.</italic> have recently screened and identified decursin as an inhibitor of the &#x3b2;-catenin signaling using HEK293 cells overexpressing &#x3b2;-catenin/TCF reporter gene (<xref ref-type="bibr" rid="B56">Song et&#xa0;al., 2007</xref>). Further studies have shown that decursin promotes the proteasomal degradation of &#x3b2;-catenin in a &#x3b2;-TrCP-dependent but GSK3&#x3b2;-independent manner (<xref ref-type="bibr" rid="B56">Song et&#xa0;al., 2007</xref>). Epigallocatechin-3-gallate (EGCG), the most abundant polyphenol from green tea has also been characterized as an inducer of &#x3b2;-catenin protein degradation. Dashwood <italic>et al.</italic> have initially found that EGCG inhibits the &#x3b2;-catenin signaling by decreasing &#x3b2;-catenin protein levels in the nucleus, cytoplasm, and membrane-associated fraction (<xref ref-type="bibr" rid="B13">Dashwood et&#xa0;al., 2005</xref>). Moreover, EGCG has been shown to facilitate the trafficking of &#x3b2;-catenin into lysosomes, which contributes to the inhibition of &#x3b2;-catenin signaling (<xref ref-type="bibr" rid="B13">Dashwood et&#xa0;al., 2005</xref>). The inhibitory effects of EGCG on &#x3b2;-catenin signaling have further been confirmed in skin and colon cancer cells (<xref ref-type="bibr" rid="B54">Singh and Katiyar, 2013a</xref>; <xref ref-type="bibr" rid="B39">Oh et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B7">Chen et&#xa0;al., 2017</xref>). Oh et al. have reported that EGCG promotes &#x3b2;-catenin phosphorylation at Ser45 and Ser33/37 and proteasomal degradation in a &#x3b2;-TrCP-dependent manner (<xref ref-type="bibr" rid="B39">Oh et&#xa0;al., 2014</xref>). Chen <italic>et al.</italic> have shown that EGCG suppresses the properties of cancer stem cells (CSCs), inhibits proliferation, and induces apoptosis in colon cancer cells (<xref ref-type="bibr" rid="B7">Chen et&#xa0;al., 2017</xref>).</p>
</sec>
<sec id="s3_4">
<title>Inhibit &#x3b2;-Catenin Nuclear Translocation</title>
<p>&#x3b2;-Catenin acts as a coactivator for TCF/LEF-mediated transcription when the cytoplasmic &#x3b2;-catenin enters the nucleus and forms the &#x3b2;-catenin/TCF/LEF complex. Several natural products have been demonstrated to inhibit the nuclear translocation of &#x3b2;-catenin (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>), thereby inhibiting cancer cell growth and inducing apoptosis (<xref ref-type="bibr" rid="B23">Jaiswal et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B53">Shukla et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B29">Li et&#xa0;al., 2009</xref>; <xref ref-type="bibr" rid="B28">Leow et&#xa0;al., 2010</xref>; <xref ref-type="bibr" rid="B3">Anitha et&#xa0;al., 2013</xref>). Shukla <italic>et al.</italic> have reported that apigenin, a plant flavonoid has potent chemopreventive efficacy in TRAMP mice by preventing prostate tumorigenesis and metastasis and improving their overall survival (<xref ref-type="bibr" rid="B53">Shukla et&#xa0;al., 2007</xref>). Further studies have shown that apigenin decreases the nuclear level of &#x3b2;-catenin and increases the cytoplasmic level of E-cadherin in prostate cancer DU145 cells <italic>in vitro</italic> and in prostate tumors from TRAMP mice <italic>in vivo</italic> (<xref ref-type="bibr" rid="B53">Shukla et&#xa0;al., 2007</xref>). The well-known chemopreventive agent curcumin, a dietary polyphenol from the ginger family <italic>Curcuma longa</italic> has been shown to down-regulate the nuclear level of &#x3b2;-catenin and disrupt the binding of &#x3b2;-catenin/TCF/LEF to the promoter DNA, thus blocking &#x3b2;-catenin-dependent gene expression, inhibiting cell viability, migration, and invasion, and inducing cell cycle arrest at the G2/M phase and apoptosis in osteosarcoma and colon cancer cells (<xref ref-type="bibr" rid="B23">Jaiswal et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B28">Leow et&#xa0;al., 2010</xref>). Jaiswal <italic>et al.</italic> have also found that curcumin promotes caspase-3-mediated degradation of &#x3b2;-catenin, E-cadherin, and APC, which may cause the loss of cell-cell adhesion (<xref ref-type="bibr" rid="B23">Jaiswal et&#xa0;al., 2002</xref>).</p>
<p>Ellagic acid, a nature-derived polyphenol has been found to suppress the development of oral carcinomas in the 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis model (<xref ref-type="bibr" rid="B3">Anitha et&#xa0;al., 2013</xref>). Its anticancer efficacy has been attributed to the inhibition of &#x3b2;-catenin nuclear translocation, while inactivation of NF-&#x3ba;B by ellagic acid may contribute to the inhibition of the &#x3b2;-catenin signaling (<xref ref-type="bibr" rid="B3">Anitha et&#xa0;al., 2013</xref>). In addition, isoeleutherine and toxoflavin (PKF118-310) have been shown to decrease the nuclear accumulation of &#x3b2;-catenin without affecting its cytoplasmic expression level (<xref ref-type="bibr" rid="B29">Li et&#xa0;al., 2009</xref>; <xref ref-type="bibr" rid="B28">Leow et&#xa0;al., 2010</xref>). PKF118-310 has also been found to inhibit the viability, migration, and invasion and induce cell cycle arrest at the G2/M phase and apoptosis in osteosarcoma U2OS cells (<xref ref-type="bibr" rid="B28">Leow et&#xa0;al., 2010</xref>).</p>
</sec>
<sec id="s3_5">
<title>Others</title>
<p>Several natural products have been reported to inhibit the &#x3b2;-catenin signaling by targeting the upstream regulators without direct effects on &#x3b2;-catenin itself (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). Zhu et al. have recently identified a plant-derived sesquiterpene lactone, parthenolide as a small-molecule inhibitor of the &#x3b2;-catenin signaling through a high-throughput screening (<xref ref-type="bibr" rid="B83">Zhu et&#xa0;al., 2018</xref>). It has further been found that parthenolide directly binds to the ribosome protein RPL10, blocks the protein synthesis of TCF4/LEF1, and decreases their protein levels, therefore inhibiting &#x3b2;-catenin/TCF/LEF-mediated gene transcription and the proliferation of colon cancer cells, without affecting the stability and subcellular distribution of &#x3b2;-catenin (<xref ref-type="bibr" rid="B83">Zhu et&#xa0;al., 2018</xref>). Gu et al. have found that berbamine, an alkaloid from traditional Chinese medicine <italic>Berberis amurensis</italic> specifically binds to the ATP-binding pocket of CaMKII &#x3b3; and inhibits its kinase activity, thereby inhibiting its downstream targets, including &#x3b2;-catenin (<xref ref-type="bibr" rid="B18">Gu et&#xa0;al., 2012</xref>). It has been further found that berbamine induces apoptotic and autophagic death of leukemia cells <italic>in vitro</italic> and suppresses tumor growth in mice bearing tyrosine kinase inhibitors (TKI)-resistant K562 or primary chronic myeloid leukemia (CML) xenograft tumors <italic>in vivo</italic> (<xref ref-type="bibr" rid="B18">Gu et&#xa0;al., 2012</xref>).</p>
<p>Natural products that restore the E-cadherin/&#x3b2;-catenin complex have been found to prevent cancer metastasis (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>) (<xref ref-type="bibr" rid="B24">Kandouz et&#xa0;al., 2010</xref>). Kandouz <italic>et al.</italic> have found that <italic>Teucrium polium</italic> plant extract (TPPE) enhances the formation of E-cadherin/&#x3b2;-catenin complex, inhibits &#x3b2;-catenin phosphorylation, and reduces invasion and motility of prostate cancer PC3 and DU145 cells (<xref ref-type="bibr" rid="B24">Kandouz et&#xa0;al., 2010</xref>). TPPE has also been shown to inhibit prostate cancer cell proliferation and induce cell cycle arrest at the S phase (<xref ref-type="bibr" rid="B24">Kandouz et&#xa0;al., 2010</xref>). In addition, several other natural products (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>), including alkaloid-enriched extract of <italic>Uncaria tomentosa</italic>, dinactin, caffeoylquinic acids, and chromomycins A2 and A3 have shown inhibitory effects on the &#x3b2;-catenin signaling in cancer cells; however, their detailed mechanisms of action are not clear yet (<xref ref-type="bibr" rid="B19">Gurrola-Diaz et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B60">Taira et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B62">Toume et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B22">Hussain et&#xa0;al., 2019</xref>).</p>
</sec>
</sec>
<sec id="s4" sec-type="conclusions">
<title>Conclusions and Future Perspectives</title>
<p>Thanks to the substantial advances in understanding the molecular basis of cancer initiation, progression, metastasis, and drug resistance, several promising molecular targets have been characterized for cancer drug discovery, including &#x3b2;-catenin (<xref ref-type="bibr" rid="B12">Cui et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B44">Qi et&#xa0;al., 2020</xref>). Considering the critical role of &#x3b2;-catenin signaling in cancer development and progression, several targeting strategies have been developed to inhibit &#x3b2;-catenin, resulting in the identification of various types of &#x3b2;-catenin inhibitors (<xref ref-type="bibr" rid="B26">Krishnamurthy and Kurzrock, 2018</xref>; <xref ref-type="bibr" rid="B50">Qin et&#xa0;al., 2018b</xref>). Natural products and natural product-derived compounds remain an important source for the discovery and development of new anticancer drugs (<xref ref-type="bibr" rid="B45">Qian et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B49">Qin et&#xa0;al., 2018a</xref>; <xref ref-type="bibr" rid="B14">Davison and Brimble, 2019</xref>). Several natural products have been shown to inhibit the &#x3b2;-catenin signaling <italic>via</italic> different molecular mechanisms, including, but not limited to, 1) down-regulating &#x3b2;-catenin expression, 2) modulating &#x3b2;-catenin phosphorylation and inducing its inactivation, 3) promoting &#x3b2;-catenin protein ubiquitination and proteasomal degradation, 4) inhibiting &#x3b2;-catenin nuclear translocation, and 5) other.</p>
<p>The majority of natural product &#x3b2;-catenin inhibitors have been shown to down-regulate &#x3b2;-catenin expression at protein and/or mRNA levels and suppress cancer cell growth <italic>in vitro</italic> and <italic>in vivo</italic>. However, the detailed molecular mechanisms for the down-regulation of &#x3b2;-catenin expression by these natural products are not clear yet, which largely hinders the further development of these natural products as anticancer agents. Of note, simply reducing the expression of an oncogene may not only induce cancer cell death but also cause other adverse effects (<xref ref-type="bibr" rid="B67">Wang et&#xa0;al., 2019</xref>). It has been found that &#x3b2;-catenin interacts with E-cadherin to stabilize cell-cell adhesion and prevent metastasis (<xref ref-type="bibr" rid="B21">Huber and Weis, 2001</xref>). Therefore, down-regulating the expression of membrane-bound &#x3b2;-catenin may promote metastasis, while targeting active &#x3b2;-catenin without affecting the &#x3b2;-catenin/E-cadherin complex is critical for developing safe and effective anticancer agent.</p>
<p>Inhibiting active &#x3b2;-catenin through modulating &#x3b2;-catenin phosphorylation and promoting its proteasomal degradation in the cytoplasm and/or inhibiting the translocation of &#x3b2;-catenin from cytoplasm to nucleus is more promising than reducing the level of &#x3b2;-catenin in whole cells. Although several natural products have been identified to inhibit the &#x3b2;-catenin signaling through these mechanisms of action, it is still unclear whether &#x3b2;-catenin is the real molecular target of these natural products. Therefore, the precise mechanisms of action, especially binding mechanisms should be further investigated. If the binding of these natural products to &#x3b2;-catenin is confirmed, it may be considered to develop &#x3b2;-catenin PROTACs (proteolysis targeting chimeras) by using these compounds for cancer prevention and therapy (<xref ref-type="bibr" rid="B37">Neklesa et&#xa0;al., 2017</xref>). Moreover, further evaluation of these compounds in more clinically relevant cancer models should be performed in the future.</p>
</sec>
<sec id="s5">
<title>Author Contributions</title>
<p>J-JQ conceptualized the manuscript. W-KY, Z-YX, LY, SM, BX, and X-DC collected the literature, wrote the manuscript and made the figures. J-JQ edited and made significant revisions to the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s6" sec-type="funding-information">
<title>Funding</title>
<p>This study was supported by National Natural Science Foundation of China (81903842), Program of Zhejiang Provincial TCM Sci-tech Plan (2020ZZ005), and Zhejiang Chinese Medical University Startup Funding (111100E014).</p>
</sec>
<sec id="s7">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank the current and former members of our laboratories and collaborators for their contributions to the publications cited in this review article. The research fields in natural products and &#x3b2;-catenin are rapidly growing, and we apologize for not being able to cite all the recent publications, due to space limitation.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aberle</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Bauer</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Stappert</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Kispert</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Kemler</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>beta-catenin is a target for the ubiquitin-proteasome pathway</article-title>. <source>EMBO J.</source> <volume>16</volume>, <fpage>3797</fpage>&#x2013;<lpage>3804</lpage>. doi: <pub-id pub-id-type="doi">10.1093/emboj/16.13.3797</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amit</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Hatzubai</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Birman</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Andersen</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Ben-Shushan</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Mann</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2002</year>). <article-title>Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway</article-title>. <source>Genes Dev.</source> <volume>16</volume>, <fpage>1066</fpage>&#x2013;<lpage>1076</lpage>. doi: <pub-id pub-id-type="doi">10.1101/gad.230302</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anitha</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Priyadarsini</surname> <given-names>R. V.</given-names>
</name>
<name>
<surname>Kavitha</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Thiyagarajan</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Nagini</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Ellagic acid coordinately attenuates Wnt/beta-catenin and NF-kappaB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis</article-title>. <source>Eur. J. Nutr.</source> <volume>52</volume>, <fpage>75</fpage>&#x2013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00394-011-0288-y</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baskar</surname> <given-names>A. A.</given-names>
</name>
<name>
<surname>Ignacimuthu</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Paulraj</surname> <given-names>G. M.</given-names>
</name>
<name>
<surname>Al Numair</surname> <given-names>K. S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Chemopreventive potential of beta-Sitosterol in experimental colon cancer model&#x2013;an in vitro and In vivo study</article-title>. <source>BMC Complement Altern. Med.</source> <volume>10</volume>, <fpage>24</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1472-6882-10-24</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bi</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>W.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Anticancer activity of Panax notoginseng extract 20(S)-25-OCH3-PPD: Targetting beta-catenin signalling</article-title>. <source>Clin. Exp. Pharmacol. Physiol.</source> <volume>36</volume>, <fpage>1074</fpage>&#x2013;<lpage>1078</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1681.2009.05203.x</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z. H.</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X. P.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>K. Q.</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>W.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>20(S)-ginsenoside Rh2 inhibits the proliferation and induces the apoptosis of KG-1a cells through the Wnt/beta-catenin signaling pathway</article-title>. <source>Oncol. Rep.</source> <volume>36</volume>, <fpage>137</fpage>&#x2013;<lpage>146</lpage>. doi: <pub-id pub-id-type="doi">10.3892/or.2016.4774</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X. Q.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>J. Y.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>C. F.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>(-)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/beta-Catenin Pathway</article-title>. <source>Nutrients</source> <volume>9</volume>, <fpage>572</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu9060572</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X. Q.</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>J. Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Phenethyl isothiocyanate inhibits colorectal cancer stem cells by suppressing Wnt/beta-catenin pathway</article-title>. <source>Phytother. Res.</source> <volume>32</volume>, <fpage>2447</fpage>&#x2013;<lpage>2455</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ptr.6183</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>a). <article-title>Taraxasterane-type triterpene and neolignans from Geum japonicum Thunb. var. chinense F. Bolle</article-title>. <source>Planta Med.</source> <volume>77</volume>, <fpage>2061</fpage>&#x2013;<lpage>2065</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0031-1280091</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>X. R.</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>H. Z.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W. D.</given-names>
</name>
</person-group> (<year>2011</year>b). <article-title>Chemical constituents of plants from the genus Geum</article-title>. <source>Chem. Biodivers</source> <volume>8</volume>, <fpage>203</fpage>&#x2013;<lpage>222</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cbdv.200900347</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Therapeutic potential of targeting the Wnt/beta-catenin signaling pathway in colorectal cancer</article-title>. <source>BioMed. Pharmacother.</source> <volume>110</volume>, <fpage>473</fpage>&#x2013;<lpage>481</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2018.11.082</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Qu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Ke</surname> <given-names>X.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Is beta-Catenin a Druggable Target for Cancer Therapy</article-title>? <source>Trends Biochem. Sci.</source> <volume>43</volume>, <fpage>623</fpage>&#x2013;<lpage>634</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tibs.2018.06.003</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dashwood</surname> <given-names>W. M.</given-names>
</name>
<name>
<surname>Carter</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Al-Fageeh</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Dashwood</surname> <given-names>R. H.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Lysosomal trafficking of beta-catenin induced by the tea polyphenol epigallocatechin-3-gallate</article-title>. <source>Mutat. Res.</source> <volume>591</volume>, <fpage>161</fpage>&#x2013;<lpage>172</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mrfmmm.2005.03.029</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davison</surname> <given-names>E. K.</given-names>
</name>
<name>
<surname>Brimble</surname> <given-names>M. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Natural product derived privileged scaffolds in drug discovery</article-title>. <source>Curr. Opin. Chem. Biol.</source> <volume>52</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cbpa.2018.12.007</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W. D.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Yehuda</surname> <given-names>A. G.</given-names>
</name>
<name>
<surname>Ashby</surname> <given-names>C. R.</given-names>
<suffix>Jr.</suffix>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update</article-title>. <source>Drug Resist. Update</source> <volume>49</volume>, <fpage>100681</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drup.2020.100681</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy</article-title>. <source>Oncotarget</source> <volume>8</volume>, <fpage>329</fpage>&#x2013;<lpage>344</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.13393</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W. D.</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>H. Z.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Two new monoterpene alkaloid derivatives from the roots of Incarvillea arguta</article-title>. <source>Arch. Pharm. Res.</source> <volume>34</volume>, <fpage>199</fpage>&#x2013;<lpage>202</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12272-011-0203-3</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Gan</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Lou</surname> <given-names>G.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>CaMKII gamma, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine</article-title>. <source>Blood</source> <volume>120</volume>, <fpage>4829</fpage>&#x2013;<lpage>4839</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood-2012-06-434894</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurrola-Diaz</surname> <given-names>C. M.</given-names>
</name>
<name>
<surname>Garcia-Lopez</surname> <given-names>P. M.</given-names>
</name>
<name>
<surname>Gulewicz</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Pilarski</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Dihlmann</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Inhibitory mechanisms of two Uncaria tomentosa extracts affecting the Wnt-signaling pathway</article-title>. <source>Phytomedicine</source> <volume>18</volume>, <fpage>683</fpage>&#x2013;<lpage>690</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.phymed.2010.11.002</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Wogonin induced G1 cell cycle arrest by regulating Wnt/beta-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells</article-title>. <source>Toxicology</source> <volume>312</volume>, <fpage>36</fpage>&#x2013;<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tox.2013.07.013</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname> <given-names>A. H.</given-names>
</name>
<name>
<surname>Weis</surname> <given-names>W. I.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin</article-title>. <source>Cell</source> <volume>105</volume>, <fpage>391</fpage>&#x2013;<lpage>402</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00330-0</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussain</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Dar</surname> <given-names>M. S.</given-names>
</name>
<name>
<surname>Bano</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Hossain</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Basit</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Bhat</surname> <given-names>A. Q.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Identification of dinactin, a macrolide antibiotic, as a natural product-based small molecule targeting Wnt/beta-catenin signaling pathway in cancer cells</article-title>. <source>Cancer Chemother. Pharmacol</source>. <volume>84</volume>, <fpage>551</fpage>&#x2013;<lpage>559</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-019-03870-x</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaiswal</surname> <given-names>A. S.</given-names>
</name>
<name>
<surname>Marlow</surname> <given-names>B. P.</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Narayan</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells</article-title>. <source>Oncogene</source> <volume>21</volume>, <fpage>8414</fpage>&#x2013;<lpage>8427</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1205947</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandouz</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Alachkar</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Dekhil</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Chehna</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Yasmeen</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>Teucrium polium plant extract inhibits cell invasion and motility of human prostate cancer cells via the restoration of the E-cadherin/catenin complex</article-title>. <source>J. Ethnopharmacol.</source> <volume>129</volume>, <fpage>410</fpage>&#x2013;<lpage>415</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jep.2009.10.035</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>W. K.</given-names>
</name>
<name>
<surname>Bach</surname> <given-names>D. H.</given-names>
</name>
<name>
<surname>Ryu</surname> <given-names>H. W.</given-names>
</name>
<name>
<surname>Oh</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Park</surname> <given-names>H. J.</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>J. Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Cytotoxic activities of Telectadium dongnaiense and its constituents by inhibition of the Wnt/beta-catenin signaling pathway</article-title>. <source>Phytomedicine</source> <volume>34</volume>, <fpage>136</fpage>&#x2013;<lpage>142</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.phymed.2017.08.008</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnamurthy</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Kurzrock</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors</article-title>. <source>Cancer Treat Rev.</source> <volume>62</volume>, <fpage>50</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ctrv.2017.11.002</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Imm</surname> <given-names>J. Y.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>S. H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>beta-Catenin Mediates Anti-adipogenic and Anticancer Effects of Arctigenin in Preadipocytes and Breast Cancer Cells</article-title>. <source>J. Agric. Food Chem.</source> <volume>65</volume>, <fpage>2513</fpage>&#x2013;<lpage>2520</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jafc.7b00112</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leow</surname> <given-names>P. C.</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Ong</surname> <given-names>Z. Y.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Ee</surname> <given-names>P. L.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells</article-title>. <source>Invest. New Drugs</source> <volume>28</volume>, <fpage>766</fpage>&#x2013;<lpage>782</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10637-009-9311-z</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Ohtsuki</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Koyano</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Kowithayakorn</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Ishibashi</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>New Wnt/beta-catenin signaling inhibitors isolated from Eleutherine palmifolia</article-title>. <source>Chem. Asian J.</source> <volume>4</volume>, <fpage>540</fpage>&#x2013;<lpage>547</lpage>. doi: <pub-id pub-id-type="doi">10.1002/asia.200800354</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-kappaB</article-title>. <source>Clin. Cancer Res.</source> <volume>19</volume>, <fpage>2917</fpage>&#x2013;<lpage>2928</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3258</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Semenov</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Han</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Baeg</surname> <given-names>G. H.</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2002</year>). <article-title>Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism</article-title>. <source>Cell</source> <volume>108</volume>, <fpage>837</fpage>&#x2013;<lpage>847</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0092-8674(02)00685-2</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>H. P.</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Z. H.</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>S. X.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>D. F.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>C. R.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Inhibition of intestinal adenoma formation in APC(Min/+) mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsuta</article-title>. <source>PloS One</source> <volume>7</volume>, <fpage>e33243</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0033243</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Hua</surname> <given-names>H.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>The natural agent rhein induces beta-catenin degradation and tumour growth arrest</article-title>. <source>J. Cell Mol. Med.</source> <volume>22</volume>, <fpage>589</fpage>&#x2013;<lpage>599</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jcmm.13346</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mineda</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Nishimura</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kagawa</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Takiguchi</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Kawakita</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Abe</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Resveratrol suppresses proliferation and induces apoptosis of uterine sarcoma cells by inhibiting the Wnt signaling pathway</article-title>. <source>Exp. Ther. Med.</source> <volume>17</volume>, <fpage>2242</fpage>&#x2013;<lpage>2246</lpage>. doi: <pub-id pub-id-type="doi">10.3892/etm.2019.7209</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitani</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Harada</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Tanimori</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Nakano</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Inui</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Yamaji</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Resveratrol inhibits hypoxia-inducible factor-1alpha-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer</article-title>. <source>J. Nutr. Sci. Vitaminol. (Tokyo)</source> <volume>60</volume>, <fpage>276</fpage>&#x2013;<lpage>282</lpage>. doi: <pub-id pub-id-type="doi">10.3177/jnsv.60.276</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nag</surname> <given-names>S. A.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M. H.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action</article-title>. <source>Front. Pharmacol.</source> <volume>3</volume>, <elocation-id>25</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2012.00025</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neklesa</surname> <given-names>T. K.</given-names>
</name>
<name>
<surname>Winkler</surname> <given-names>J. D.</given-names>
</name>
<name>
<surname>Crews</surname> <given-names>C. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Targeted protein degradation by PROTACs</article-title>. <source>Pharmacol. Ther.</source> <volume>174</volume>, <fpage>138</fpage>&#x2013;<lpage>144</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.02.027</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname> <given-names>D. J.</given-names>
</name>
<name>
<surname>Cragg</surname> <given-names>G. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019</article-title>. <source>J. Nat. Prod.</source> <volume>83</volume>, <fpage>770</fpage>&#x2013;<lpage>803</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b01285</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Gwak</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Park</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>C. S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Green tea polyphenol EGCG suppresses Wnt/beta-catenin signaling by promoting GSK-3beta- and PP2A-independent beta-catenin phosphorylation/degradation</article-title>. <source>Biofactors</source> <volume>40</volume>, <fpage>586</fpage>&#x2013;<lpage>595</lpage>. doi: <pub-id pub-id-type="doi">10.1002/biof.1185</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orford</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Crockett</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Jensen</surname> <given-names>J. P.</given-names>
</name>
<name>
<surname>Weissman</surname> <given-names>A. M.</given-names>
</name>
<name>
<surname>Byers</surname> <given-names>S. W.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin</article-title>. <source>J. Biol. Chem.</source> <volume>272</volume>, <fpage>24735</fpage>&#x2013;<lpage>24738</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.272.40.24735</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozawa</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Baribault</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Kemler</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species</article-title>. <source>EMBO J.</source> <volume>8</volume>, <fpage>1711</fpage>&#x2013;<lpage>1717</lpage>. doi: <pub-id pub-id-type="doi">10.1002/j.1460-2075.1989.tb03563.x</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozawa</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Ringwald</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kemler</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source> <volume>87</volume>, <fpage>4246</fpage>&#x2013;<lpage>4250</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.87.11.4246</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pai</surname> <given-names>S. G.</given-names>
</name>
<name>
<surname>Carneiro</surname> <given-names>B. A.</given-names>
</name>
<name>
<surname>Mota</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Costa</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Leite</surname> <given-names>C. A.</given-names>
</name>
<name>
<surname>Barroso-Sousa</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Wnt/beta-catenin pathway: modulating anticancer immune response</article-title>. <source>J. Hematol. Oncol.</source> <volume>10</volume>, <fpage>101</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13045-017-0471-6</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname> <given-names>S. M.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>X. D.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W. D.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet</article-title>? <source>Front. Cell Dev. Biol.</source> <volume>8</volume>, <elocation-id>233</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2020.00233</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Nag</surname> <given-names>S. A.</given-names>
</name>
<name>
<surname>Su</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Voruganti</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents</article-title>. <source>Curr. Cancer Drug Targets</source> <volume>13</volume>, <fpage>519</fpage>&#x2013;<lpage>541</lpage>. doi: <pub-id pub-id-type="doi">10.2174/15680096113139990031</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Voruganti</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W. D.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2015</year>a). <article-title>Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation</article-title>. <source>Oncotarget</source> <volume>6</volume>, <fpage>2623</fpage>&#x2013;<lpage>2640</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.3098</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Voruganti</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W. D.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2015</year>b). <article-title>Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA</article-title>. <source>Oncotarget</source> <volume>6</volume>, <fpage>33106</fpage>&#x2013;<lpage>33119</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.5851</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Novel natural product therapeutics targeting both inflammation and cancer</article-title>. <source>Chin. J. Nat. Med.</source> <volume>15</volume>, <fpage>401</fpage>&#x2013;<lpage>416</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1875-5364(17)30062-6</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Hunt</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>a). <article-title>Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine</article-title>. <source>Genes Dis.</source> <volume>5</volume>, <fpage>204</fpage>&#x2013;<lpage>219</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.gendis.2018.07.002</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Deokar</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Buolamwini</surname> <given-names>J. K.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>b). <article-title>Inhibiting beta-Catenin by beta-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy</article-title>. <source>Front. Pharmacol.</source> <volume>9</volume>, <elocation-id>5</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2018.00005</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riggleman</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Schedl</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Wieschaus</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Spatial expression of the Drosophila segment polarity gene armadillo is posttranscriptionally regulated by wingless</article-title>. <source>Cell</source> <volume>63</volume>, <fpage>549</fpage>&#x2013;<lpage>560</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0092-8674(90)90451-J</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting beta-catenin-mediated angiogenesis</article-title>. <source>Tumour. Biol.</source> <volume>37</volume>, <fpage>12791</fpage>&#x2013;<lpage>12803</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13277-016-5251-3</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukla</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Maclennan</surname> <given-names>G. T.</given-names>
</name>
<name>
<surname>Flask</surname> <given-names>C. A.</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Resnick</surname> <given-names>M. I.</given-names>
</name>
<etal/>
</person-group>. (<year>2007</year>). <article-title>Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice</article-title>. <source>Cancer Res.</source> <volume>67</volume>, <fpage>6925</fpage>&#x2013;<lpage>6935</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0717</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Katiyar</surname> <given-names>S. K.</given-names>
</name>
</person-group> (<year>2013</year>a). <article-title>Green tea polyphenol, (-)-epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting beta-catenin signaling</article-title>. <source>Toxicol. Appl. Pharmacol.</source> <volume>273</volume>, <fpage>418</fpage>&#x2013;<lpage>424</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.taap.2013.09.021</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Katiyar</surname> <given-names>S. K.</given-names>
</name>
</person-group> (<year>2013</year>b). <article-title>Honokiol inhibits non-small cell lung cancer cell migration by targeting PGE(2)-mediated activation of beta-catenin signaling</article-title>. <source>PloS One</source> <volume>8</volume>, <fpage>e60749</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0060749</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>G. Y.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>J. H.</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Park</surname> <given-names>B. S.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>D. E.</given-names>
</name>
<name>
<surname>Oh</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of beta-catenin</article-title>. <source>Mol. Pharmacol.</source> <volume>72</volume>, <fpage>1599</fpage>&#x2013;<lpage>1606</lpage>. doi: <pub-id pub-id-type="doi">10.1124/mol.107.040253</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>K. S.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Jing</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>T. D.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>J. P.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/beta-catenin in SW480 human colon cancer cells</article-title>. <source>BMC Cancer</source> <volume>11</volume>, <fpage>307</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2407-11-307</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamos</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Weis</surname> <given-names>W. I.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>The beta-catenin destruction complex</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>5</volume>, <fpage>a007898</fpage>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a007898</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suh</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Afaq</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Mukhtar</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways</article-title>. <source>Carcinogenesis</source> <volume>30</volume>, <fpage>300</fpage>&#x2013;<lpage>307</lpage>. doi: <pub-id pub-id-type="doi">10.1093/carcin/bgn269</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taira</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Uehara</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Tsuchida</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Ohmine</surname> <given-names>W.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Inhibition of the beta-catenin/Tcf signaling by caffeoylquinic acids in sweet potato leaf through down regulation of the Tcf-4 transcription</article-title>. <source>J. Agric. Food Chem.</source> <volume>62</volume>, <fpage>167</fpage>&#x2013;<lpage>172</lpage>. doi: <pub-id pub-id-type="doi">10.1021/jf404411r</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Shizukaol D, a Dimeric Sesquiterpene Isolated from Chloranthus serratus, Represses the Growth of Human Liver Cancer Cells by Modulating Wnt Signalling Pathway</article-title>. <source>PloS One</source> <volume>11</volume>, <fpage>e0152012</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0152012</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toume</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Tsukahara</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Arai</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Ishibashi</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Chromomycins A2 and A3 from marine actinomycetes with TRAIL resistance-overcoming and Wnt signal inhibitory activities</article-title>. <source>Mar. Drugs</source> <volume>12</volume>, <fpage>3466</fpage>&#x2013;<lpage>3476</lpage>. doi: <pub-id pub-id-type="doi">10.3390/md12063466</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Sang</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Shan</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via beta-catenin-dependent signaling</article-title>. <source>Oncol. Rep.</source> <volume>26</volume>, <fpage>1149</fpage>&#x2013;<lpage>1156</lpage>. doi: <pub-id pub-id-type="doi">10.3892/or.2011.1400</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>G. W.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>X. R.</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>Y. H.</given-names>
</name>
<name>
<surname>Shan</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>H. Z.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Inula sesquiterpenoids: structural diversity, cytotoxicity and anti-tumor activity</article-title>. <source>Expert Opin. Invest. Drugs</source> <volume>23</volume>, <fpage>317</fpage>&#x2013;<lpage>345</lpage>. doi: <pub-id pub-id-type="doi">10.1517/13543784.2014.868882</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Guan</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X.</given-names>
</name>
</person-group> (<year>2018</year>a). <article-title>Therapeutic effects of beta-elemene via attenuation of the Wnt/beta-catenin signaling pathway in cervical cancer cells</article-title>. <source>Mol. Med. Rep.</source> <volume>17</volume>, <fpage>4299</fpage>&#x2013;<lpage>4306</lpage>. doi: <pub-id pub-id-type="doi">10.3892/mmr.2018.8455</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Tao</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>b). <article-title>Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms</article-title>. <source>Carcinogenesis</source> <volume>39</volume>, <fpage>1026</fpage>&#x2013;<lpage>1036</lpage>. doi: <pub-id pub-id-type="doi">10.1093/carcin/bgy063</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Rajaei</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Hunt</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Targeting MDM2 for novel molecular therapy: Beyond oncology</article-title>. <source>Med. Res. Rev</source>. <volume>40</volume>, <fpage>856</fpage>&#x2013;<lpage>880</lpage>. doi: <pub-id pub-id-type="doi">10.1002/med.21637</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>Y. Y.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Mo</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Aspeterreurone A, a Cytotoxic Dihydrobenzofuran-Phenyl Acrylate Hybrid from the Deep-Sea-Derived Fungus Aspergillus terreus CC-S06-18</article-title>. <source>J. Nat. Prod</source>. doi: <pub-id pub-id-type="doi">10.1021/acs.jnatprod.0c00189</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname> <given-names>L. H.</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>J. F.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H. W.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Q. Y.</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/beta-catenin signaling pathway</article-title>. <source>Chin. J. Integr. Med.</source> <volume>23</volume>, <fpage>858</fpage>&#x2013;<lpage>863</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11655-017-2775-3</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieschaus</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Nusslein-Volhard</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Jurgens</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>1984</year>). <article-title>Mutations affecting the pattern of the larval cuticle inDrosophila melanogaster : III. Zygotic loci on the X-chromosome and fourth chromosome</article-title>. <source>Wilehm Roux Arch. Dev. Biol.</source> <volume>193</volume>, <fpage>296</fpage>&#x2013;<lpage>307</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF00848158</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>G.</given-names>
</name>
<name>
<surname>He</surname> <given-names>X.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Threonine 41 in beta-catenin serves as a key phosphorylation relay residue in beta-catenin degradation</article-title>. <source>Biochemistry</source> <volume>45</volume>, <fpage>5319</fpage>&#x2013;<lpage>5323</lpage>. doi: <pub-id pub-id-type="doi">10.1021/bi0601149</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Bi</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Mou</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>K.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Inhibition of beta-catenin signaling involved in the biological activities of a lignan E2S isolated from Carya cathayensis fruits</article-title>. <source>Planta Med.</source> <volume>79</volume>, <fpage>1648</fpage>&#x2013;<lpage>1652</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0033-1351020</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname> <given-names>Z. N.</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J. Q.</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>X. R.</given-names>
</name>
<name>
<surname>An</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Physalis peruviana-Derived 4beta-Hydroxywithanolide E, a Novel Antagonist of Wnt Signaling, Inhibits Colorectal Cancer In Vitro and In Vivo</article-title>. <source>Molecules</source> <volume>24</volume>, <fpage>1146</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules24061146</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Su</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Q.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Gigantol inhibits Wnt/beta-catenin signaling and exhibits anticancer activity in breast cancer cells</article-title>. <source>BMC Complement Altern. Med.</source> <volume>18</volume>, <fpage>59</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12906-018-2108-x</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Z. Y.</given-names>
</name>
<name>
<surname>Ruan</surname> <given-names>S. M.</given-names>
</name>
<name>
<surname>Mo</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>X. D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance</article-title>. <source>Mol. Cancer</source> <volume>19</volume>, <fpage>96</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-020-01219-0</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>S. D.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>H. Z.</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>Y. H.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H. L.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X. W.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Sesquiterpenoids from Inula racemosa Hook. f. inhibit nitric oxide production</article-title>. <source>Planta Med.</source> <volume>78</volume>, <fpage>166</fpage>&#x2013;<lpage>171</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0031-1280294</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>F. Y.</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Que</surname> <given-names>Z. Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y. H.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z. H.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Shikonin Inhibits the Migration and Invasion of Human Glioblastoma Cells by Targeting Phosphorylated beta-Catenin and Phosphorylated PI3K/Akt: A Potential Mechanism for the Anti-Glioma Efficacy of a Traditional Chinese Herbal Medicine</article-title>. <source>Int. J. Mol. Sci.</source> <volume>16</volume>, <fpage>23823</fpage>&#x2013;<lpage>23848</lpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms161023823</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Z.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Terphenyllin Suppresses Orthotopic Pancreatic Tumor Growth and Prevents Metastasis in Mice</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <elocation-id>457</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2020.00457</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Qu</surname> <given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Targeting the beta-catenin signaling for cancer therapy</article-title>. <source>Pharmacol. Res.</source> <volume>104794</volume>. doi: <pub-id pub-id-type="doi">10.1016/j.phrs.2020.104794</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Kuang</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Baicalin inhibits the metastasis of highly aggressive breast cancer cells by reversing epithelial-to-mesenchymal transition by targeting beta-catenin signaling</article-title>. <source>Oncol. Rep.</source> <volume>38</volume>, <fpage>3599</fpage>&#x2013;<lpage>3607</lpage>. doi: <pub-id pub-id-type="doi">10.3892/or.2017.6011</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>J. X.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>R. J.</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>X. R.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>a). <article-title>Chemical constituents of plants from the genus Euonymus</article-title>. <source>Chem. Biodivers</source> <volume>9</volume>, <fpage>1055</fpage>&#x2013;<lpage>1076</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cbdv.201100170</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>J. X.</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>X. R.</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>b). <article-title>Phenylpropanoids and lignanoids from Euonymus acanthocarpus</article-title>. <source>Arch. Pharm. Res.</source> <volume>35</volume>, <fpage>1739</fpage>&#x2013;<lpage>1747</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12272-012-1005-y</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Nie</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>X.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>The plant sesquiterpene lactone parthenolide inhibits Wnt/beta-catenin signaling by blocking synthesis of the transcriptional regulators TCF4/LEF1</article-title>. <source>J. Biol. Chem.</source> <volume>293</volume>, <fpage>5335</fpage>&#x2013;<lpage>5344</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M117.819300</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>